Akron CEO Zylberberg interviewed for the Innate Killer Summit 2018

The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as the catalyst to ensure successful clinical and commercial translation of Natural Killer (NK) cell immunotherapies. Leading up to the March 2018 event in San Diego, CA, Akron Biotechnology CEO Claudia Zylberberg, Ph.D. shared some key issues and questions arising in the NK therapy